Iaso Therapeutics, Inc.

Startup

Iaso Therapeutics is developing a novel conjugate vaccine carrier protein. This carrier is a genetically modified bacteriophage capsid protein that self-assembles into a virus-like particle with superior characteristics for delivering vaccine antigens. Licensed from Michigan State University, the platform is strengthened by a Sponsored Research Agreement with a major pharmaceutical company, commercial sale to researchers, and impressive success with federal grants raising $3 million in non-dilutive funding. Conjugate delivery includes a wide variety of antigens, including protein, peptide, polysaccharide, oligosaccharide, and small molecules to elicit a superior protective immune response as compared to other carriers currently on the market.

Iaso is working to develop a human vaccine for infectious disease to provide clinical proof of concept of the platform carrier system. Iaso is set to move into pre-clinical development of two vaccines based on oligosaccharide antigens. The first would prevent salmonella infections caused by S. paratyphi, S. enteritidis, and S. typhimurium. The second targets S. aureus and will prevent MRSA infections.

Iaso has previously raised a $1.25M Series Seed round and is now seeking to raise a Series A round of financing to advance one of the vaccines above through pre-clinical development, IND submission, and Phase I human clinical trial.

website